MOTS-c vs Retatrutide: A Research Reference
Where MOTS-c and Retatrutide overlap in the literature, and where they do not, is the substance of this reference.
Compound profiles
MOTS-c in the indexed record
Indexed output for MOTS-c stands at 255 records, a moderate literature, alongside 9 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Adv Sci (Weinh), Cardiovasc Drugs Ther, Front Endocrinol (Lausanne), spanning 2022–2025.
- Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination — Adv Sci (Weinh), 2024. PMID: 39321430
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes — Redox Biol, 2025. PMID: 40403491
- MOTS-c: Magical Molecule for Diabetic Cardiomyopathy? — Cardiovasc Drugs Ther, 2025. PMID: 40172798
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne), 2023. PMID: 36761202
Retatrutide in the indexed record
Searching Retatrutide against the PubMed index returns 180 records, a moderate evidence base, alongside 34 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Nat Med.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Nat Med, 2024. PMID: 38858523
Classification and why it matters
MOTS-c and Retatrutide sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for MOTS-c describes conditions validated for MOTS-c: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Retatrutide without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Side-by-side research profile
| Parameter | MOTS-c | Retatrutide |
|---|---|---|
| PubMed indexed records | 255 | 180 |
| Registered studies (ClinicalTrials.gov) | 9 | 34 |
| Literature depth | Moderate | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
How the literature differs
The indexed record is not symmetrical between these two compounds. MOTS-c carries 75 more indexed records than Retatrutide, which means published methodology, characterisation data and replication attempts are more readily located for MOTS-c. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (9 vs 34) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Selecting between them for a study design
MOTS-c and Retatrutide are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (MOTS-c) generally offers more methodological precedent.
Frequently asked questions
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Which of MOTS-c or Retatrutide has more published research?
MOTS-c, with 255 indexed PubMed records against 180.
Related references
- MOTS-c — product and lot documentation
- Retatrutide — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.